Jack A. Khattar - 07 Mar 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
07 Mar 2025
Net transactions value
-$726,703
Form type
4
Filing time
07 Mar 2025, 16:40:30 UTC
Previous filing
04 Mar 2025
Next filing
11 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $0 +38,640 +4.1% $0.000000 992,219 07 Mar 2025 Direct F1
transaction SUPN Common Stock Tax liability $726,703 -18,581 -1.9% $39.11 973,638 07 Mar 2025 Direct F2
holding SUPN Common Stock 1,022,450 07 Mar 2025 By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Performance Share Units Options Exercise $0 -38,640 -100% $0.000000 0 07 Mar 2025 Common Stock 38,640 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 17, 2025.
F2 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3 On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022.